Comparison of methaqualone excretion patterns using Abuscreen ONLINE and EMIT II immunoassays and GC/MS

被引:10
作者
Brenner, C
Hui, R
Passarelli, J
Wu, R
Brenneisen, R
Bracher, K
ElSohly, MA
Ghodoussi, VD
Salamone, SJ
机构
[1] ROCHE DIAGNOST SYST,SOMERVILLE,NJ 08876
[2] UNIV BERN,INST PHARM,CH-3012 BERN,SWITZERLAND
[3] ELSOHLY LABS INC,OXFORD,MS 38655
关键词
methaqualone; excretion; ONLINE; EMIT; immunoassay; GC/MS;
D O I
10.1016/0379-0738(96)01888-9
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
A study was performed to compare the ONLINE and EMIT II immunoassays with gas chromatographic/mass spectrometric (GC/MS) analysis of methaqualone metabolites on urine using samples obtained from a clinical study. Urine was collected over a 72 h period from six healthy adults (4 male, 2 female) after oral dosing with 200 mg methaqualone (MTQ). Each urine sample was analyzed by ONLINE and EMIT II. The samples were then analyzed by GC/MS, hydrolyzed with beta-glucuronidase and again analyzed by GC/MS. Both immunoassays showed greater than 600 ng/ml concentrations of drug in each sample by the second void and remained highly positive for the rest of the 72 h. Unhydrolyzed samples analyzed by GC/MS showed both low concentrations of MTQ as well as its five major hydroxylated metabolites. The hydrolyzed samples analyzed by GC/MS showed high concentrations of the hydroxylated metabolites with the 2'-hydroxy and 3'-hydroxy metabolites being present at the highest concentrations, the 4'-hydroxy metabolite at a lower amount and the 6-hydroxy and 2-hydroxy metabolites at the lowest concentrations. The GC/MS data coupled with the antibody cross-reactivity data indicate that the major species in clinical samples that cross-react in both immunoassays are the conjugated forms of the hydroxylated metabolites of MTQ. Therefore when confirming by GC/MS after an immunoassay screen it would be prudent to confirm for the major hydroxylated metabolites as glucuronides of MTQ instead of the parent drug.
引用
收藏
页码:31 / 41
页数:11
相关论文
共 11 条
[1]   URINARY-EXCRETION OF C-HYDROXY DERIVATIVES OF METHAQUALONE IN MAN [J].
BURNETT, D ;
REYNOLDS, CN ;
WILSON, K ;
FRANCIS, JR .
XENOBIOTICA, 1976, 6 (02) :125-134
[2]   DETECTION OF METHAQUALONE AND ITS METABOLITES IN URINE [J].
BURNETT, D ;
GOUDIE, JH ;
SHERRIFF, JM .
JOURNAL OF CLINICAL PATHOLOGY, 1969, 22 (05) :602-&
[3]  
CHRISTENSON JG, 1977, Patent No. 4053459
[4]  
CJHRISTENSON JG, 1980, Patent No. 4182879
[5]  
ERICSSON O, 1977, DRUG METAB DISPOS, V5, P497
[6]  
HEYNDRICKX A, 1969, J EUR TOXICOL, V11, P56
[7]  
KAZYAK L, 1977, CLIN CHEM, V23, P2001
[8]   URINARY-EXCRETION OF METHAQUALONE-N-OXIDE IN MAN [J].
REYNOLDS, CN ;
WILSON, K ;
BURNETT, D .
XENOBIOTICA, 1976, 6 (02) :113-124
[9]   BIOAVAILABILITY OF METHAQUALONE [J].
SMYTH, RD ;
LEE, JK ;
POLK, A ;
CHEMBURKAR, PB ;
SAVACOOL, AM .
JOURNAL OF CLINICAL PHARMACOLOGY, 1973, 13 (10) :391-400
[10]  
WILSON K, 1981, European Journal of Drug Metabolism and Pharmacokinetics, V6, P289